Real-time monitoring of Nuclear factor κB activity in cultured cells and in animal models

Molecular Imaging

Volumn 8, Issue 5, 2009, Pages 278-290

  Badr, Christian E ^a,b,c   Niers, Johanna M ^a,b,c   Tjon Kon fat, Lee Ann ^a,b,c   Noske, David P ^a,b,c   Wurdinger, Thomas ^a,b,c   Tannous, Bakhos A ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL MODEL; CONDITIONED MEDIUM; CULTURED CELL; HIGHLY SENSITIVE; HUMAN DISORDERS; IN-VITRO; NON-INVASIVE MONITORING; NUCLEAR FACTORS; PROMOTER ELEMENTS; REAL TIME; REAL TIME MONITORING; REPORTER SYSTEMS; SECRETED ALKALINE PHOSPHATASE; TUMOR DEVELOPMENT; TUMOR FORMATION;

ANIMALS; BLOOD; TRANSCRIPTION FACTORS; TUMORS;

ENDOTHELIAL CELLS;

ALKALINE PHOSPHATASE; ANTIINFLAMMATORY AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ANIMAL MODEL; ARTICLE; BLOOD; CELL LINE; DRUG EFFECT; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; URINE;

ALKALINE PHOSPHATASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE; CELL LINE, TUMOR; HUMANS; MICE; MICE, NUDE; MODELS, ANIMAL; NF-KAPPA B; SIGNAL TRANSDUCTION; SULFASALAZINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349671585     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2009.00026     Document Type: Article

References (60)

1. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986; 46: 705-16.
2. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-60.
3. Hayden M. S., Ghosh S. Shared principles in NF-kappa B signaling. Cell 2008;132:344-62.
4. Verma I. M., Stevenson JK, Schwarz EM, et al. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev 1995;9:2723-5.
5. Pahl HL. Activators and target genes of Rel/NF-kappa B transcription factors. Oncogene 1999;18:6853-66.
6. Coussens L. M., Werb Z. Infl ammation and cancer. Nature 2002;420:860-7.
7. Karin M, Greten FR. NF-kappa B: linking infl ammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5:749-59.
8. Escarcega R. O., Fuentes-Alexandro S, Garcia-Carrasco M, et al. The transcription factor nuclear factor-kappa B and cancer. Clin Oncol (R Coll Radiol) 2007;19:154-61.
9. Lee C. H., Jeon YT, Kim SH, Song YS. NF-kappa B as a potential molecular target for cancer therapy. Biofactors 2007;29:19-35.
10. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999;18:6938-47.
11. Bentires-Alj M, Barbu V, Fillet M, et al. NF-kappa B transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003;22:90-7.
12. Karin M. Nuclear factor-kappa B in cancer development and progression. Nature 2006;441:431-6.
13. Sadikot R. T., Blackwell TS. Bioluminescence imaging. Proc Am Thorac Soc 2005;2:537-40.
14. Wurdinger T, Badr C, Pike L, et al. A secreted luciferase for ex vivo monitoring of in vivo processes. Nat Methods 2008;5:171-3.
15. Duan H, Heckman CA, Boxer LM. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t (14;18) lymphomas. Mol Cell Biol 2005; 25: 1608-19.
16. Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodefi ciency virus in T cells. Nature 1987;326:711-3.
17. Tannous B. A., Kim DE, Fernandez JL, et al. Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol Ther 2005;11:435-43.
18. Saeki Y, Breakefi eld XO, Chiocca EA. Improved HSV-1 amplicon packaging system using ICP27-deleted, oversized HSV-1 BAC DNA. Methods Mol Med 2003;76:51-60.
19. Sena-Esteves M, Tebbets JC, Steffens S, et al. Optimized largescale production of high titer lentivirus vector pseudotypes. J Virol Methods 2004;122:131-9.
20. Chung J. H., Whiteley M, Felsenfeld G. A 5' element of the chicken beta-globin domain serves as an insulator in human erythroid cells and protects against position effect in Drosophila. Cell 1993;74:505-14.
21. Kashima T, Vinters HV, Campagnoni AT. Unexpected expression of intermediate fi lament protein genes in human oligodendroglioma cell lines. J Neuropathol Exp Neurol 1995;54:23-31.
22. Hung G, Li X, Faudoa R, et al. Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2. Int J Oncol 2002;20:475-82.
23. Rizzo M. A., Springer GH, Granada B, Piston DW. An improved cyan fl uorescent protein variant useful for FRET. Nat Biotechnol 2004;22:445-9.
24. Brach M. A., Hass R, Sherman ML, et al. Ionizing radiation induces expression and binding activity of the nuclear factor kappa B. J Clin Invest 1991; 88: 691-5.
25. Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodefi ciency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci U S A 1989;86:2336-40.
26. Prosch S, Staak K, Stein J, et al. Stimulation of the human cytomegalovirus IE enhancer/promoter in HL-60 cells by TNFalpha is mediated via induction of NF-kappa B. Virology 1995;208:197-206.
27. Svensson R. U., Barnes JM, Rokhlin OW, et al. Chemotherapeutic agents up-regulate the cytomegalovirus promoter: implications for bioluminescence imaging of tumor response to therapy. Cancer Res 2007;67:10445-54.
28. Arlt A, Vorndamm J, Breitenbroich M, et al. Inhibition of NF-kappa B sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 2001; 20: 859-68.
29. Ishii H, Takada K. Bleomycin induces E-selectin expression in cultured umbilical vein endothelial cells by increasing its mRNA levels through activation of NF-kappa B/Rel. Toxicol Appl Pharmacol 2002;184:88-97.
30. Prabhakar S, Messerli SM, Stemmer-Rachamimov AO, et al. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. Cancer Gene Ther 2007;14:460-7.
31. Tannous B. A., Grimm J, Perry KF, et al. Metabolic biotinylation of cell surface receptors for in vivo imaging. Nat Methods 2006;3:391-6.
32. Guo R. X., Qiao YH, Zhou Y, et al. Increased staining for phosphorylated AKT and nuclear factor-kappa B p65 and their relationship with prognosis in epithelial ovarian cancer. Pathol Int 2008;58:749-56.
33. Korkolopoulou P, Levidou G, Saetta AA, et al. Expression of nuclear factor-kappa B in human astrocytomas: relation to pI kappa Ba, vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival. Hum Pathol 2008;39:1143-52.
34. McNulty S. E., del Rosario R, Cen D, et al. Comparative expression of NFkappa B proteins in melanocytes of normal skin vs. benign intradermal naevus and human metastatic melanoma biopsies. Pigment Cell Res 2004; 17: 173-80.
35. Shukla S, MacLennan GT, Fu P, et al. Nuclear factor-kappa B/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia 2004;6:390-400.
36. Smith D, Shimamura T, Barbera S, Bejcek BE. NF-kappa B controls growth of glioblastomas/astrocytomas. Mol Cell Biochem 2008;307:141-7.
37. Zhang Z, Ma J, Li N, et al. Expression of nuclear factor-kappa B and its clinical signifi cance in nonsmall-cell lung cancer. Ann Thorac Surg 2006;82:243-8.
38. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specifi c inhibitor of nuclear factor kappa B. J Clin Invest 1998;101:1163-74.
39. Weber C. K., Liptay S, Wirth T, et al. Suppression of NF-kappa B activity by sulfasalazine is mediated by direct inhibition of Ikappa B kinases alpha and beta. Gastroenterology 2000;119:1209-18.
40. Hehner S P, Heinrich M, Bork PM, et al. Sesquiterpene lactones specifi cally inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta. J Biol Chem 1998;273:1288-97.
41. DeBusk L. M., Massion P P, Lin P C. Ikappa B kinase-alpha regulates endothelial cell motility and tumor angiogenesis. Cancer Res 2008;68:10223-8.
42. Wurdinger T, Tannous BA, Saydam O, et al. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell 2008;14:382-93.
43. Jimi E, Ghosh S. Role of nuclear factor-kappa B in the immune system and bone. Immunol Rev 2005;208:80-7.
44. Bhakar A. L., Tannis LL, Zeindler C, et al. Constitutive nuclear factor-kappa B activity is required for central neuron survival. J Neurosci 2002;22:8466-75.
45. Schmidt-Ullrich R, Memet S, Lilienbaum A, et al. NF-kappa B activity in transgenic mice: developmental regulation and tissue specifi city. Development 1996;122:2117-28.
46. Carlsen H, Moskaug JO, Fromm SH, Blomhoff R. In vivo imaging of NF-kappa B activity. J Immunol 2002; 168:1441-6.
47. Magness S. T., Jijon H, Van Houten Fisher N, et al. In vivo pattern of lipopolysaccharide and anti-CD3-induced NF-kappa B activation using a novel gene-targeted enhanced GFP reporter gene mouse. J Immunol 2004;173:1561-70.
48. Haridas V, Shrivastava A, Su J, et al. VEGI, a new member of the TNF family, activates nuclear factor-kappa B and c-Jun. N-terminal kinase and modulates cell growth. Oncogene 1999;18:6496-504.
49. Gross S, Piwnica-Worms D. Real-time imaging of ligandinduced IKK activation in intact cells and in living mice. Nat Methods 2005;2:607-14.
50. Badr C. E., Hewett JW, Breakefi eld XO, Tannous BA. A highly sensitive assay for monitoring the secretory pathway and ER stress. PLoS ONE 2007;2:e571.
51. Shukla S, Gupta S. Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF) -kappa B activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappa B-responsive genes. Clin Cancer Res 2004;10:3169-78.
52. Chilov D, Kukk E, Taira S, et al. Genomic organization of human and mouse genes for vascular endothelial growth factor C. J Biol Chem 1997;272:25176-83.
53. Hou B, Eren M, Painter CA, et al. Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappa B site. J Biol Chem 2004;279:18127-36.
54. Vincenti M P, Coon CI, Brinckerhoff CE. Nuclear factor kappa B/p50 activates an element in the distal matrix metal loproteinase 1 promoter in interleukin-1beta-stimulated synovial fi broblasts. Arthritis Rheum 1998;41:1987-94.
55. Huang S, Pettaway CA, Uehara H, et al. Blockade of NF-kappa B activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001;20:4188-97.
56. Li L, Gondi CS, Dinh DH, et al. Transfection with anti-p65 intrabody suppresses invasion and angiogenesis in glioma cells by blocking nuclear factor-kappa B transcriptional activity. Clin Cancer Res 2007;13:2178-90.
57. Ghosh A, Roy A, Liu X, et al. Selective inhibition of NF-kappa B activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 2007;104:18754-9.
58. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
59. Neurath M. F., Becker C, Barbulescu K. Role of NF-kappa B in immune and infl ammatory responses in the gut. Gut 1998;43:856-60.
60. Barnes P. J., Adcock IM. Transcription factors and asthma. Eur Respir J 1998;12:221-34.